Myeloproliferative neoplasm in accelerated phase (MPN-AP) research hub

Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis - FAMy

This study, called FAMy, is looking at a new combination of two medicines, Inrebic and Onureg, for people with a specific type of bone marrow disorder called accelerated phase myelofibrosis. It aims to find the safest and most effective dose of this new treatment.